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Summary
Genetic deletion of fragile Xmental retardation protein
(FMRP) hasbeenshown toenhancemGluR-dependent
long-term depression (LTD). Herein, we demonstrate
that mGluR-LTD induces a transient, translation-
dependent increase in FMRP that is rapidly degraded
by the ubiquitin-proteasome pathway. Moreover, pro-
teasome inhibitors abolished mGluR-LTD, and LTD
was absent in mice that overexpress human FMRP.
Neither translation nor proteasome inhibitors blocked
the augmentation of mGluR-LTD in FMRP-deficient
mice. In addition, mGluR-LTD is associated with rapid
increases in the protein levels of FMRP target mRNAs
in wild-type mice. Interestingly, the basal levels of
these proteins were elevated and their synthesis
was improperly regulated duringmGluR-LTD in FMRP-
deficient mice. Our findings indicate that hippocampal
mGluR-LTD requires the rapid synthesis and degrada-
tion of FMRP and that mGluR-LTD triggers the synthe-
sis of FMRP binding mRNAs. These findings indicate
that the translation, ubiquitination, and proteolysis of
FMRP functions as a dynamic regulatory system for
controlling synaptic plasticity.
Introduction
Fragile X syndrome (FXS) is the most common inherited
disease causing mental retardation, affecting approxi-
mately 1:4000 males and 1:8000 females (Turner et al.,
1996). The syndrome is characterized by moderate to
severe mental retardation, mild facial dysmorphism, and
macro-orchidism. FXS typically results from the expan-
sion of a CGG repeat sequence in the 50 untranslated
region of fragile X mental retardation gene FMR1. The
trinucleotide repeat expansion and subsequent hy-
permethylation cause transcriptional silencing of the
FMR1 gene, resulting in the loss of the fragile X mental
retardation protein (FMRP; Warren and Sherman, 2001;
Jin and Warren, 2003; O’Donnell and Warren, 2002).
Fmr1 knockout mice, which serve as an animal model
for FXS, have been generated and characterized (Bakker
et al., 1994). In general, these mice exhibit several be-
havioral phenotypes consistent with FXS (Kooy, 2003).
FMRP is an mRNA binding protein thought to regulate
translation of specific mRNAs, including its own mRNA
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2001; Miyashiro et al., 2003; Zhang et al., 2001). Previous
studies have shown that FMRP is colocalized with poly-
ribosomes in the neuronal soma as well as in dendritic
spines, which suggests the possibility that FMRP is
involved in local dendritic protein synthesis (Stefani
et al., 2004). Metabotropic glutamate receptor-depen-
dent long-term depression (mGluR-LTD) is a dendritic
protein synthesis-dependent form of synaptic plasticity
that can be induced reliably by the selective group I
mGluRagonist (RS)-3,5-dihydroxyphenylglycine (DHPG;
Huber et al., 2001; Hou and Klann, 2004). FMRP is likely
to be critically involved in the biochemical regulation of
translation during mGluR-LTD. For example, it has been
reported that mGluR-LTD is augmented in Fmr1 knock-
out mice (Huber et al., 2002). In addition, several studies
suggest that FMRP is translated in response to stimula-
tion of group I mGluRs in synaptosomes as well as in cul-
tured cortical and hippocampal neurons (Weiler et al.,
1997; Todd et al., 2003a, 2003b; Antar et al., 2004). Over-
all these previous findings have led to the mGluR theory
of fragile X mental retardation (Bear et al., 2004). We
have investigated several assumptions of this theory,
including whether mGluR-LTD is associated with in-
creased synthesis of FMRP and proteins encoded by
FMRP binding mRNAs, and whether the enhanced
mGluR-LTD previously observed in the Fmr1 knockout
mouse is due to exaggerated protein synthesis. In this
manuscript, we describe the results of experiments that
have tested these assumptions of the mGluR theory.
Herein, we show that mGluR-LTD induced by DHPG in
hippocampal area CA1 results in the rapid translation of
FMRP that is dependent on the group I mGluR subtype
mGluR5. To our surprise, we found that the rapid in-
crease in FMRP levels associated with mGluR-LTD was
followed by the ubiquitination and rapid degradation of
FMRP through the ubiquitin-proteasome pathway. We
observed that the inhibition of the ubiquitin-proteasome
pathway abrogated mGluR-LTD, as did the overexpres-
sion of FMRP. Consistent with previous studies, we
foundthatmGluR-LTDwasaugmented inFmr1knockout
mice compared to wild-type mice. We also found that
mGluR-LTD in wild-type mice was associated with rapid
increases in the levels of proteins whose mRNAs bind to
FMRP and that these increases were abolished in Fmr1
knockout mice. Interestingly, in contrast to mGluR-LTD
in wild-type mice, we found that both protein synthesis
and proteasome inhibitors had no effect on mGluR-LTD
in Fmr1 knockout mice. Taken together, these findings
indicate that hippocampal mGluR-LTD requires the rapid
synthesis and degradation of FMRP and that mGluR-
LTD triggers the synthesis of FMRP binding mRNAs.
Results
mGluR-LTD Induced by DHPG Triggers a Rapid,
Protein Synthesis-Dependent Increase in FMRP
Levels in Hippocampal Area CA1
One of the assumptions of the mGluR theory of fragile X
mental retardation is that FMRP synthesis is enhanced
Neuron
442Figure 1. DHPG Induces a Protein Synthesis- and mGluR5-Dependent Increase of FMRP in Hippocampal Area CA1
(A) Representative Western blots showing that DHPG treatment increases FMRP levels. Hippocampal slices were treated with DHPG (50 mM) for
10 min. Slices then were incubated with ACSF in the absence of DHPG for the indicated times and the levels of FMRP was assessed via Western
blot analysis.
(C) Representative Western blots showing that DHPG-induced increase of FMRP is protein synthesis dependent. Hippocampal slices were
preincubated with anisomycin (Aniso, 20 mM) for 30 min and then exposed to DHPG (50 mM) for 10 min. The levels of FMRP were assessed via
Western blot analysis.
(B and D) Quantitative analysis of cumulative Western blot experiments. FMRP immunoreactivity was normalized to tubulin immunoreactivity.
Values are means6 SEM and are expressed as a percentage of control samples ([B], n = 4–5; [D], n = 5). *p < 0.05 (unpaired t test), as compared
with control.
(E) Representative Western blots showing that mGluR5 antagonist blocked DHPG-induced increase in FMRP levels. Hippocampal slices were
preincubated with mGluR1 antagonist LY367385 (LY367, 100 mM) or mGluR5 antagonist MPEP (20 mM) for 30 min and then exposed to DHPG
(50 mM) for 10 min. The levels of FMRP were assessed via Western blot analysis.
(F) Quantitative analysis of cumulative Western blot experiments. FMRP immunoreactivity was normalized to tubulin immunoreactivity. Values
are means6 SEM and are expressed as a percentage of control samples (n = 8). *p < 0.001 as compared with control; #p < 0.05 as compared with
DHPG (ANOVA).in response to activation of group I mGluRs (Bear et al.,
2004). Consistent with this idea, it was previously shown
that activation of group I mGluRs increases the syn-
thesis of FMRP in synaptosomes and cortical neurons
(Weiler et al., 1997; Todd et al., 2003b). Therefore, we
determined whether FMRP synthesis was increased in
association with mGluR-LTD. To induce mGluR-LTD,
we applied DHPG (50 mM) to hippocampal slices for
10 min and then measured FMRP levels from area CA1
homogenates at various times after washout of DHPG.
We observed a rapid increase in FMRP levels after ap-
plication of DHPG, which was followed by a rapid de-
cline in FMRP levels that reached basal levels 10 min
after washout of DHPG (Figures 1A and 1B). These
data indicate that mGluR-LTD is associated with a
rapid, albeit transient, increase in FMRP in hippocampal
area CA1.
We proceeded to examine whether the rapid increase
in FMRP associated with mGluR-LTD was regulated
at the level of translation. Pretreatment of hippocampal
slices with the protein synthesis inhibitor anisomycin(20 mM) completely abrogated the DHPG-induced
increase in FMRP (Figures 1C and 1D). These data are
consistent with the notion that the DHPG-induced
increase in FMRP is protein synthesis dependent.
It is well known that group I mGluRs consist of two
subtypes, mGluR1 and mGluR5, and that both of these
receptors contribute to the induction mGluR-LTD in
mouse hippocampal area CA1 (Hou and Klann, 2004).
To identify which group I mGluR subtype(s) was respon-
sible for the rapid increase in FMRP associated with
mGluR-LTD, we applied DHPG to hippocampal slices
in the presence of either LY367385, a selective antago-
nist of mGluR1, or MPEP, a specific antagonist of
mGluR5. As with previous experiments, we found that
FMRP was significantly elevated rapidly after the induc-
tion of mGluR-LTD and that this elevation was blocked
by MPEP (Figures 1E and 1F). In contrast, we found that
the mGluR1 antagonist LY367385 did not affect the LTD-
induced increase in FMRP levels (Figures 1E and 1F).
Incubation of slices with either LY367385 or MPEP alone
did not alter basal levels of FMRP (LY367385, 104%6 8%
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443Figure 2. DHPG-Induced Increase of FMRP Is Present in Both Soma and Dendrites of Pyramidal Cells in Hippocampal Area CA1
Confocal images were obtained from slices that were labeled using antibodies specific for MAP2 and FMRP. FMRP labeling is indicated by red,
MAP2 labeling is indicated by green, and dual labeling is indicated by yellow.
(A) (a and c) Sham-treated slices. (b and d) Slices treated with 50 mM DHPG for 10 min.
(B) Cumulative histogram showing that DHPG increased the level of FMRP in both the soma and dendrites. Values are means 6 SEM and are
expressed as a percentage of control (n = 5–9). *p < 0.05 (unpaired t test), as compared with control.
(C) Slices from Fmr1 knockout mice. (a and c) Sham-treated slices. (b and d) Slices treated with 50 mM DHPG for 10 min. Stratum pyramidale (s.p.)
and stratum radiatum (s.r.) are indicated. Scale bar, 50 mm.of control, n = 7; MPEP, 100% 6 17% of control, n = 7).
Taken together, these results indicate that the rapid
increase of FMRP depends on activation of mGluR5
rather than mGluR1.
To investigate the subcellular localization of the
LTD-associated increase in FMRP levels, we employed
double-labeling immunofluorescence. In control condi-
tions, FMRP was primarily expressed in the soma of
pyramidal neurons of area CA1, but FMRP immunofluo-
rescence could be detected in dendrites (Figures 2Aa
and 2Ac). Following the induction of mGluR-LTD, we
found that the intensity of FMRP immunofluorescence
increased most obviously in the soma of CA1 pyramidal
neurons. In addition, we also observed increased FMRP
levels in proximal dendrites of CA1 pyramidal neurons
(Figures 2Ab and 2Ad). FMRP immunofluorescence
was not observed in hippocampal slices from FMRP-
deficient mice, indicating that the immunostaining we
observed in wild-type mice was specific (Figures 2Be–
2Bh). In addition, we utilized DAPI to counterstain DNA
to investigate whether mGluR-LTD increased FMRP
levels in the nucleus. We observed that under basal con-
ditions, there is FMRP present in the nucleus and that
DHPG treatment increases the levels of nuclear FMRP
(see Figure S1 in the Supplemental Data available with
this article online). These findings indicate that mGluR-
LTD is associated with a rapid increase in FMRP in the
soma, nucleus, and proximal dendrites in hippocampal
area CA1.The Ubiquitin-Proteasome Pathway Regulates
FMRP Levels during mGluR-LTD
As shown in Figure 1, 10 min after washout of DHPG, the
increased FMRP levels declined back to basal levels.
This finding suggested the intriguing possibility that
FMRP, in addition to being rapidly synthesized, is rap-
idly degraded after the induction of mGluR-LTD. One
of the primary pathways that regulate the degradation
of proteins is the ubiquitin-proteasome system. Most
cellular proteins in eukaryotic cells are targeted for deg-
radation by the 26S proteasome (Coux et al., 1996). To
test whether the 26S proteasome was involved in the
DHPG-induced rapid degradation of FMRP, we incu-
bated hippocampal slices with the proteasomal inhibitor
MG132 (5 mM) prior to the induction of mGluR-LTD. In
contrast to our findings in Figure 1A, we observed that
MG132 blocked the reduction in FMRP levels 10 min
after washout of DHPG (Figures 3A and 3B). We per-
formed a similar set of experiments with the more spe-
cific proteasomal inhibitor clasto-lactacystin b-lactone
(lactacystin, 5 mM) and found that it also blocked the de-
gradation of FMRP associated with mGluR-LTD (Figures
3C and 3D). We also found that MG132 and lactacystin
had a trend to increase FMRP levels, indicating that
FMRP might be constitutively regulated by the protein
degradation pathway. However, we observed that coin-
cubating DHPG with either MG132 or lactacystin did not
induce a further increase in FMRP compared to DHPG-
induced FMRP (Figures 3A–3D). Immunofluorescence
Neuron
444Figure 3. The Proteasome Pathway Regulates FMRP Degradation
(A) Representative Western blots showing that proteasome inhibitor MG132 blocked FMRP degradation. Hippocampal slices were incubated
with the proteasome inhibitor MG132 (MG, 5 mM) 30 min before, during the 10 min application of DHPG (50 mM), 0 and 10 min after washout
of DHPG. The levels of FMRP were assessed via Western blot analysis.
(C) Representative Western blots showing that the proteasome inhibitor lactacystin blocked FMRP degradation. Hippocampal slices were in-
cubated with the proteasome inhibitor lactacystin (Lac, 5 mM) 30 min before, during DHPG (50 mM) 10 min, and 0 and 10 min after washout of
DHPG. The levels of FMRP were assessed via Western blot analysis.
(B and D) Quantitative analysis of the cumulative Western blot experiments. FMRP immunoreactivity was normalized to tubulin immunoreactiv-
ity. Values are means6 SEM and are expressed as a percentage of control samples ([B], n = 4–7; [D], n = 4–9). *p < 0.05 (one-way ANOVA analysis
followed by Newman-Keuls post test), as compared with control.
(E) Confocal images were obtained from slices that were labeled using antibodies specific for MAP2 and FMRP. FMRP labeling is indicated by
red, MAP2 labeling is indicated by green, and dual labeling is indicated by yellow. (a and b) Sham-treated slices. (c and d) Slices treated with
DHPG. (e and f) Slices treated with 50 mM DHPG for 10 min then incubated with ASCF for 10 min (Dw). (g and h) Slices were incubated with
the proteasome inhibitor MG132 (5 mM) 30 min before, during the 10 min application of DHPG (50 mM), and 10 min after washout of DHPG
(Dw + MG132). Stratum pyramidale (s.p.) and Stratum radiatum (s.r.) are indicated. Scale bar, 50 mm.experiments revealed that the DHPG-induced increases
in FMRP levels were regulated by the ubiquitin-protea-
some pathway in both the soma and dendrites of hippo-
campal pyramidal cells (Figure 3E). These findings are
consistent with the notion that FMRP is regulated dy-
namically during mGluR-LTD, with rapid synthesis fol-
lowed by rapid degradation.
The role of ubiquitin in protein degradation is its most
extensively studied function; polyubiquitin chains are
covalently attached to target proteins and serve as a
signal for their recognition and degradation by the 26S
proteasome (Coux et al., 1996). Therefore, we hypothe-
sized that FMRP was ubiquitinated following the induc-
tion of mGluR-LTD. To test this hypothesis, we induced
mGluR-LTD with DHPG for 10 min and then immunopre-
cipitated FMRP 0 and 10 min after washout of DHPG. We
then probed the immunoprecipitates on Western blots
with an antibody specific for ubiquitin. We observed that
mGluR-LTD was associated with, based on the molecu-
lar weight of FMRP, an increase in the monoubiquitina-
tion of FMRP 10 min after washout of DHPG (Figures 4A
and 4B). Although monoubiquitination in some instancescan target proteins for degradation (Haglund et al.,
2003), it is much more common for polyubiquitination
to target proteins for degradation. To determine whether
we could detect polyubiquitinated FMRP, mGluR-LTD
was induced with DHPG in the presence of the protea-
some inhibitor MG132. Under these conditions, we ob-
served several higher molecular weight polyubiquiti-
nated species of FMRP, one of which had an apparent
molecular weight of approximately 110 kDa that was in-
creased 10 min after washout of DHPG (Figures 4C and
4D). Taken together, these results are consistent with
the hypothesis that mGluR-LTD is associated with in-
creased ubiquitination and degradation of FMRP and
suggest the intriguing possibility that mGluR-LTD may
require activation of the ubiquitin-proteasome pathway
and the subsequent degradation of FMRP.
The Ubiquitin-Proteasome Pathway
Regulates mGluR-LTD
Recent evidence indicates that ubiquitination and pro-
teasome-mediated degradation has a role in the molec-
ular mechanisms underlying synaptic plasticity (Cline,
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445Figure 4. mGluR-LTD Triggers Ubiquitination of FMRP and Inhibition of the Proteasome Pathway Blocks mGluR-LTD
(A and C) DHPG treatment increases ubiquitination of FMRP. Fmr1 knockout and wild-type slices were treated with DHPG (50 mM, 10 min), and
area CA1 was frozen, dissected, and homogenized at 0 and 10 min after washout of DHPG (Dw10) or at 0 and 10 min after washout of DHPG in the
presence of MG132 (MG) (C). FMRP was immunoprecipitated (IP), and samples were immunoblotted (IB) with an antibody to ubiquitin (upper
panel) and immunoblotted with an antibody to FMRP (lower panel).
(B and D) Quantification of the cumulative FMRP ubiquitination experiments. Ubiquitinated FMRP immunoreactivity was normalized to IgG
immunoreactivity. Values are means 6 SEM and are expressed as a percentage of control (n = 4).
(E–H) mGluR-LTD was induced by incubation of slices with DHPG (50 mM) for 10 min in the presence of vehicle, MG132 (5 mM), or lactacystin
(5 mM).The vehicle, MG132, or lactacystin was present in the perfusing solution 20 min before and during the treatment with DHPG as indicated
by the bars.
(E) Sample fEPSPs from hippocampal slices illustrate the effect of MG132 on mGluR-LTD.
(F) Ensemble averages of slope of the fEPSPs over the entire time course of the experiment demonstrates that MG132 blocks mGluR-LTD
(DHPG + vehicle, open square, n = 8; DHPG + MG132, closed square, n = 8).
(G) Sample fEPSPs from hippocampal slices illustrate the effect of lactacystin on mGluR-LTD.
(H) Ensemble averages of slope of the fEPSPs over the entire time course of the experiment demonstrates that lactacystin blocks mGluR-LTD
(DHPG + vehicle, open square, n = 11; DHPG + lactacystin, closed square, n = 10).
Calibration: (E and G) 5 mV, 2 ms. In (F) and (H), the cumulative data are plotted as mean 6 SEM.2003; Hegde, 2004; Bingol and Schuman, 2005). To de-
termine whether proteasomal degradation of proteins is
required for mGluR-LTD, we induced mGluR-LTD with
DHPG in the Schaffer collateral pathway of mouse hip-
pocampal slices perfused with either vehicle or the pro-
teasome inhibitor MG132 (5 mM). LTD was induced reli-
ably when the slices were incubated with DHPG (50 mM
for 10 min) in the presence of vehicle (Figures 4E–4H).
In contrast, inhibition of proteasome activity with MG132
significantly blocked the late phase of DHPG-induced
mGluR-LTD (Figures 4E and 4F; DHPG + vehicle, fEPSP
slope = 76% 6 4% of baseline, n = 8; DHPG + MG132,
fEPSP slope = 99% 6 3% of baseline, n = 8; p < 0.01).
To confirm a role for the proteasome pathway in
mGluR-LTD, we repeated the experiments with lacta-
cystin, a more specific proteasome inhibitor. Lacta-
cystin also blocked the late phase of DHPG-induced
mGluR-LTD (Figures 4G and 4H; DHPG + vehicle, fEPSPslope = 73%6 2% of baseline, n = 11; DHPG + lactacys-
tin, fEPSP slope = 101% 6 3% of baseline, n = 10;
p < 0.001) Taken together, these findings indicated that
mGluR-LTD requires not only protein synthesis, but
also protein degradation via the ubiquitin-proteasome
pathway.
Overexpressing FMRP Abolishes mGluR-LTD
in Wild-Type and FMRP-Deficient Mice
We found that inhibition of the ubiquitin-proteasome
pathway during DHPG application maintains FMRP
levels above baseline levels (Figure 3) and prevents
mGluR-LTD (Figure 4). In addition, it has been shown
that mGluR-LTD is enhanced in FMRP-deficient mice
(Huber et al., 2002). Taken together, these findings
suggest the possibility that the inhibitors of the ubiqui-
tin-proteasome pathway block mGluR-LTD via the
maintenance of elevated levels of FMRP. To test this
Neuron
446Figure 5. Overexpressing FMRP Abolishes mGluR-LTD in Wild-Type and Fmr1 Knockout Mice
(A) Input-output curve (n = 9–14) and (B) PPF (n = 8–11) experiments show that basic synaptic transmission was not different in the four mouse
genotypes. Error bars are SEM.
(C) mGluR-LTD was induced by incubation of slices with DHPG (50 mM) for 10 min. Sample fEPSPs from hippocampal slices illustrate the effect of
overexpressing FMRP on mGluR-LTD in Fmr1 knockout (Fmr1 KO + FMR1 YAC) mice and wild-type (FMR1 YAC) mice.
(D) Ensemble averages of slope of the fEPSPs over the entire time course of the experiment demonstrates that overexpressing FMRP abolishes
the enhancement of mGluR-LTD in Fmr1 knockout mice (wild-type, open square, n = 14; Fmr1 KO, closed square, n = 13; Fmr1 KO/FMR1 YAC,
closed circle, n = 17; FMR1 YAC, open circle, n = 11).
Calibration: (C) 5 mV, 2 ms. In (D), the cumulative data are plotted as mean 6 SEM.possibility, we employed yeast artificial chromosome
(YAC) transgenic mice that overexpress the human
FMRP protein (Peier et al., 2000). Breeding of heterozy-
gous male FMR1 YAC transgenic mice with female het-
erozygous Fmr1 knockout mice resulted in four litter-
mate genotypes: wild-type, FMR1 YAC transgenic
mice, Fmr1 knockout mice, and Fmr1 knockout mice
harboring the FMR1 YAC transgene. Normal morphol-
ogy has been shown in light microscopic examination
of brain sections prepared from all four genotypes (Peier
et al., 2000). Basal synaptic transmission was similar in
the four genotypes as evidenced by similar synaptic
input-output relationship in control and mutant slices
(Figure 5A). Paired-pulse facilitation (PPF), a presynaptic
form of short-term synaptic plasticity, also was similar
between the four genotypes of mice at multiple inter-
pulse intervals (Figure 5B). Consistent with the work of
Huber and colleagues, we found that mGluR-LTD was
exaggerated in Fmr1 knockout mice compared to wild-
type mice (Figures 5C and 5D; Fmr1 KO mice, fEPSP
slope = 67% 6 3% of baseline, n = 13; wild-type mice,
fEPSP slope = 83% 6 4% of baseline, n = 14; p <
0.001). We also observed that the enhanced mGluR-
LTD in Fmr1 knockout mice was significantly decreasedwhen these mice also expressed the human FMR1 YAC
transgene (Figures 5C and 5D—Fmr1KO, fEPSP = 67%6
3% of baseline, n = 13; Fmr1 KO + FMR1 YAC, fEPSP =
91%6 7% of baseline, n = 17; p < 0.01). Finally, we found
that mGluR-LTD was completely abolished in FMR1
YAC transgenic mice compared to wild-type littermates
(Figures 5C and 5D; FMR1 YAC, fEPSP slope = 99% 6
6% of baseline, n = 11; wild-type, fEPSP slope = 83% 6
4% of baseline, n = 14; p < 0.001). Taken together, these
findings indicate that overexpression of FMRP inhibits
mGluR-LTD either in wild-type or Fmr1 knockout mice.
Moreover, these findings suggest the possibility that
the blockade of mGluR-LTD by inhibition of the ubiqui-
tin-proteasome pathway is due to sustaining elevated
levels of FMRP after application of DHPG.
Inhibition of the Ubiquitin-Proteasome Pathway
Does Not Block Enhanced mGluR-LTD in Fmr1
Knockout Mice
If sustained, elevated levels of FMRP contribute to the
elimination of mGluR-LTD by inhibition of the ubiquitin-
proteasome pathway, then one would predict that
the proteasome inhibitors would not block mGluR-
LTD in Fmr1 knockout mice. To test this prediction, we
Synthesis and Degradation of FMRP during mGluR-LTD
447Figure 6. The Proteasome Inhibitors MG132 and Lactacystin Do Not Block Enhanced mGluR-LTD in Fmr1 Knockout Mice
mGluR-LTD was induced by incubation of slices with DHPG (50 mM) for 10 min in the presence of either vehicle or MG132 (20 mM). Either the
vehicle or the MG132 were present in the perfusing solution 20 min before and during the treatment with DHPG as indicated by the bars.
(A) Sample fEPSPs from hippocampal slices illustrate the effect of MG132 on mGluR-LTD in Fmr1 knockout mice.
(B) Ensemble averages of slope of the fEPSPs over the entire time course of the experiment demonstrates that MG132 does not block mGluR-
LTD in Fmr1 knockout (Fmr1 KO) mice (DHPG + vehicle, open square, n = 10; DHPG + MG132, closed square, n = 6).
(C) Sample fEPSPs from hippocampal slices illustrate the effect of lactacystin on mGluR-LTD in Fmr1 knockout mice.
(D) Ensemble averages of slope of the fEPSPs over the entire time course of the experiment demonstrates that lactacystin does not block mGluR-
LTD in Fmr1 knockout (Fmr1 KO) mice (DHPG + vehicle, open square, n = 7; DHPG + lactacystin, closed square, n = 8).
Calibration: (A and C) 5 mV, 2 ms. In (B) and (D), the cumulative data are plotted as mean 6 SEM.determined whether the proteasome inhibitors MG132
and lactacystin could block DHPG-induced mGluR-
LTD in Fmr1 knockout mice. In contrast to our findings
in wild-type mice, we found that neither MG132 nor lac-
tacystin blocked mGluR-LTD induced by DHPG in Fmr1
knockout mice (Figures 6A and 6B; DHPG + vehicle,
fEPSP slope = 72% 6 5% of baseline, n = 10; DHPG +
MG132, fEPSP slope = 84% 6 6% of baseline, n = 6;
p > 0.05; Figures 6C and 6D; DHPG + vehicle, fEPSP
slope = 70% 6 6% of baseline, n = 7; DHPG + lactacys-
tin, fEPSP slope = 68%6 8% of baseline, n = 8; p > 0.05).
These observations are consistent with the idea that
abrogation of mGluR-LTD by inhibition of the ubiquitin-
proteasome pathway is in part due to sustained elevated
levels of FMRP.
Differential Translational Regulation of FMRP
Binding mRNAs in Wild-Type and Fmr1
Knockout Mice
Another assumption of the mGluR hypothesis of fragile
X mental retardation is that the translation of mRNAs
that bind FMRP will be enhanced in response to activa-
tion of group I mGluRs and that their translation will be
excessive in Fmr1 knockout mice (Bear et al., 2004).
To test this possibility, we examined the levels of several
proteins whose mRNAs are known to bind FMRP.
Although FMRP is known to bind to a plethora of mRNAs
and regulate their translation (Brown et al., 2001; Chen
et al., 2003; Darnell et al., 2001; Kanai et al., 2004; Miya-
shiro et al., 2003; Zhang et al., 2001), we decided to ex-
amine the microtubule associated protein 1B (MAP1B)
that has been shown to be translationally regulated by
FMRP in Drosophila (Zhang et al., 2001) and in mouse
cortical neurons (Lu et al., 2004). We also examined
a-CaMKII, the a subunit of Ca2+/calmodulin-dependent
protein kinase II, an intensely studied protein kinaseknown for its role in synaptic plasticity (Soderling, 2000).
a-CaMKII is highly expressed at the synapse where its
mRNA is translationally regulated (Bagni et al., 2000).
As shown in Figures 7A–7D, the basal levels of MAP1B
and a-CaMKII in hippocampal area CA1 of Fmr1 knock-
out mice were increased compared to those of wild-type
mice. Inducing mGluR-LTD with DHPG significantly
increased the levels of MAP1B and a-CaMKII in wild-
type mice (Figures 7A–7D). In contrast, mGluR-LTD
was not associated with an additional increase in the
levels of either MAP1B or a-CaMKII in Fmr1 knockout
mice. We also investigated whether there were differ-
ences in the levels of extracellular signal-regulated
kinase (ERK), whose mRNA does not bind to FMRP, dur-
ing mGluR-LTD in wild-type and Fmr1 knockout mice. In
contrast to MAP1B and a-CaMKII, we found that the
basal levels of total ERK in hippocampal area CA1 of
Fmr1 knockout mice were similar to the levels of total
ERK in wild-type mice (Figures 7E and 7F). These find-
ings are consistent with the idea that there is excessive
translation of MAP1B and a-CaMKII in Fmr1 knockout
mice and that FMRP binding mRNAs are translated dur-
ing mGluR-LTD in wild-type mice. However, these find-
ings also indicate that rather than an additional level of
excessive translation, mGluR-dependent translational
regulation of MAP1B and a-CaMKII is absent in Fmr1
knockout mice.
It has been shown that dual phosphorylation and acti-
vation of the ERK is associated with and necessary for
mGluR-LTD (Gallagher et al., 2004; Banko et al., 2006).
Therefore, we determined whether the mGluR-depen-
dent increase in the dual phosphorylation of ERK was al-
tered in the Fmr1 knockout mice. We observed that the
basal levels of dually phosphorylated ERK were in-
creased in Fmr1 knockout mice compared to wild-type
mice (Figures 7G and 7H). Similar to previous findings,
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448Figure 7. Regulation of MAP1B, a-CaMKII, ERK and Phospho-ERK Levels by DHPG in Wild-Type and Fmr1 Knockout (Fmr1 KO) Mice
Hippocampal slices were incubated with DHPG (50 mM) for 10 min.
(A) Representative Western blots showing differential regulation of MAP1B levels by DHPG in wild-type and Fmr1 knockout mice. The levels of
MAP1B were assessed via Western blot analysis.
(B) Quantitative analysis of cumulative Western blot experiments. MAP1B immunoreactivity was normalized to tubulin immunoreactivity. Values
are means6 SEM and are expressed as a percentage of control samples (n = 6). *p < 0.05 (unpaired t test), as compared with wild-type control.
(C) Representative Western blots showing differential regulation of a-CaMKII levels by DHPG in wild-type and Fmr1 knockout mice. The levels of
a-CaMKII were assessed via Western blot analysis.
(D) Quantitative analysis of cumulative Western blot experiments. a-CaMKII immunoreactivity was normalized to tubulin immunoreactivity.
Values are means 6 SEM and are expressed as a percentage of control samples (n = 17). *p < 0.05 (unpaired t test), as compared with wild-
type control.
(E) Representative Western blots showing regulation of total ERK (T-ERK) levels by DHPG in wild-type and Fmr1 knockout mice. The levels of
T-ERK were assessed via Western blot analysis.
(F) Quantitative analysis of cumulative Western blot experiments. T-ERK immunoreactivity was normalized to tubulin immunoreactivity. Values
are means 6 SEM and are expressed as a percentage of control samples (n = 6).
(G) Representative Western blots showing regulation of phosphorylated ERK (P-ERK) levels by DHPG in wild-type and Fmr1 knockout mice. The
levels of P-ERK were assessed via Western blot analysis.
(H) Quantitative analysis of cumulative Western blot experiments. P-ERK immunoreactivity was normalized to tubulin immunoreactivity. Values
are means6 SEM and are expressed as a percentage of control samples (n = 7). *p < 0.05 (unpaired t test), as compared with wild-type control.we found that mGluR-LTD was associated with a sig-
nificant increase in the dual phosphorylation of ERK
in wild-type mice. In contrast, in the Fmr1 knockout
mice, there was no further LTD-associated increase in
dually phosphorylated ERK (Figures 7G and 7H). These
findings indicate that mGluR-dependent activation of
the ERK signaling cascade is regulated improperly in
Fmr1 knockout mice.
Enhanced mGluR-LTD Is Dependent on Neither
Protein Synthesis nor ERK Activation in Fmr1
Knockout Mice
It has been reported that mGluR-LTD is enhanced in
Fmr1 knockout mice (Huber et al., 2002), and we have
confirmed this finding (Figure 5). To determine whether
the enhanced mGluR-LTD in Fmr1 knockout mice is due
to enhanced protein synthesis, we determined whether
the protein synthesis inhibitor anisomycin could block
the enhanced mGluR-LTD. As shown in Figure 8, apply-
ing DHPG to hippocampal slices induced a normalmGluR-LTD in wild-type that was sensitive to blockade
by anisomycin (Figures 8A and 8B; DHPG + vehicle,
fEPSP slope = 85% 6 3% of baseline, n = 14; DHPG +
anisomycin, fEPSP slope = 100% 6 3% of baseline,
n = 7; p < 0.01). In contrast, anisomycin had no effect
on mGluR-LTD in Fmr1 knockout mice (Figures 8C
and 8D; DHPG + vehicle, fEPSP slope = 72% 6 5% of
baseline, n = 13; DHPG + anisomycin, fEPSP slope =
79% 6 5% of baseline, n = 7; p > 0.05). These results
strongly suggest that the enhancement of mGluR-
LTD observed in Fmr1 knockout mice does not require
protein synthesis.
A growing body of literature has implicated ERK as an
important regulator of protein synthesis-dependent syn-
aptic plasticity (Banko et al., 2004, 2005, 2006; Kelleher
et al., 2004; Gallagher et al., 2004). However, we found
that mGluR-LTD was not associated with activation
of ERK (Figures 7G and 7H) and was not sensitive to in-
hibition of protein synthesis in Fmr1 knockout mice
(Figure 8). Therefore, we posited that the ERK pathway
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449Figure 8. Inhibition of Protein Synthesis Does Not Block Enhanced mGluR-LTD in Fmr1 Knockout Mice
mGluR-LTD was induced by incubation of slices with DHPG (50 mM) for 10 min in the presence of either vehicle or anisomycin (20 mM). Either the
vehicle or the anisomycin were present in the perfusing solution 20 min before, during, and 30 min after the treatment with DHPG, as indicated by
the bars.
(A) Sample fEPSPs from hippocampal slices illustrate the effect of anisomycin on mGluR-LTD in wild-type mice.
(B) Ensemble averages of slope of the fEPSPs over the entire time course of the experiment demonstrates that anisomycin blocked mGluR-LTD
in wild-type mice (DHPG + vehicle, open square, n = 14; DHPG + anisomycin, closed square, n = 7).
(C) Sample fEPSPs from hippocampal slices illustrate the effect of anisomycin on mGluR-LTD in Fmr1 knockout mice.
(D) Ensemble averages of slope of the fEPSPs over the entire time course of the experiment demonstrates that anisomycin did not block mGluR-
LTD in Fmr1 knockout (Fmr1 KO) mice (DHPG + vehicle, open square, n = 13; DHPG + anisomycin, closed square, n = 7).
Calibration: (A and C) 5 mV, 2 ms. In (B) and (D), the cumulative data are plotted as mean 6 SEM.would not be required for mGluR-LTD in the Fmr1
knockout mice. To test this idea, mGluR-LTD in slices
from wild-type and Fmr1 knockout mice was induced
by DHPG in the presence of the selective and mem-brane-permeable MEK inhibitor, U0126 (20 mM). Con-
sistent with previous reports, mGluR-LTD induced by
DHPG was significantly inhibited by U0126 in wild-
type slices (Figures 9A and 9B; DHPG + vehicle, fEPSPFigure 9. Inhibition of MEK-ERK Pathway Does Not Block Enhanced mGluR-LTD in Fmr1 Knockout Mice
mGluR-LTD was induced by incubation of slices with DHPG (50 mM) for 10 min in the presence of either vehicle or U0126 (20 mM). Either the
vehicle or the U0126 were present in the perfusing solution 60 min before and during the treatment with DHPG. (A) Sample fEPSPs from hippo-
campal slices illustrate the effect of U0126 on mGluR-LTD in wild-type mice.
(B) Ensemble averages of slope of the fEPSPs over the entire time course of the experiment demonstrates that U0126 blocked mGluR-LTD in
wild-type mice (DHPG + vehicle, open square, n = 7; DHPG + U0126, closed square, n = 7).
(C) Sample fEPSPs from hippocampal slices illustrate the effect of U0126 on mGluR-LTD in Fmr1 knockout mice.
(D) Ensemble averages of slope of the fEPSPs over the entire time course of the experiment demonstrates that U0126 did not block mGluR-LTD in
Fmr1 knockout (Fmr1 KO) mice (DHPG + vehicle, open square, n = 10; DHPG + U0126, closed square, n = 9).
Calibration: (A and C) 5 mV, 2 ms. In (B) and (D), the cumulative data are plotted as mean 6 SEM.
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450slope = 77% 6 2% of baseline, n = 7; DHPG + U0126,
fEPSP slope = 98% 6 4% of baseline, n = 7; p < 0.01).
In contrast, in Fmr1 knockout mice mGluR- LTD was
not affected by U0126 (Figures 9C and 9D; DHPG + ve-
hicle, fEPSP slope = 77% 6 5% of baseline, n = 10;
DHPG + U0126, fEPSP slope = 80% 6 7% of baseline,
n = 9; p > 0.05). Thus, in addition to being resistant to in-
hibition of protein synthesis, mGluR-LTD is resistant to
inhibition of the ERK signaling cascade.
Discussion
FMRP has emerged as potential key regulator of protein
synthesis-dependent synaptic plasticity in the hippo-
campus. The first suggestion of a role for FMRP in hip-
pocampal synaptic plasticity was provided by Huber
and colleagues, who demonstrated that mGluR-LTD is
enhanced in Fmr1 knockout mice (Huber et al., 2002).
Because mGluR-LTD is dependent on protein synthesis
(Huber et al., 2000), these findings, coupled with bio-
chemical studies that showed that FMRP synthesis is
enhanced in response to activation of group I mGluRs
in synaptosomes and cortical neurons (Weiler et al.,
1997; Todd et al., 2003b), have resulted in the mGluR
theory of fragile X mental retardation (Bear et al.,
2004). One of the assumptions of this theory is that
mGluR-LTD should be associated with increased syn-
thesis of FMRP. We tested this idea and found that
mGluR-LTD induced with DHPG indeed resulted in
a rapid increase in FMRP levels in area CA1 of mouse
hippocampal slices that was blocked by the protein syn-
thesis inhibitor anisomycin (Figure 1). Interestingly, we
found that the mGluR-LTD-associated increase in FMRP
levels was localized predominantly in the soma of CA1
pyramidal neurons, although elevated levels of FMRP
also could be detected in the proximal dendrites of
these neurons (Figure 2). Our results resemble those
of a previous study in cultured hippocampal neurons
that showed that membrane depolarization triggers an
mGluR-dependent increase in FMRP in the cell body
that corresponds with a loss of FMRP at synapses (Antar
et al., 2004). Because mGluR activation has been shown
to increase FMRP levels in synaptosomes (Weiler et al.,
1997), these results suggest the intriguing possibility
that FMRP may be synthesized at synapses and trans-
ported back to the soma. Alternatively, the loss of FMRP
at synapses may be due to its ubiquitination and degra-
dation (Figures 1 and 4A–4D). These possibilities remain
to be determined.
We found that the rapid, protein synthesis-dependent
increase in FMRP associated with mGluR-LTD was
blocked by the mGluR5 antagonist MPEP, but not by
the mGluR1 antagonist LY367385 (Figure 1). These find-
ings are consistent with previous findings that have
shown that DHPG-induced mGluR-LTD is inhibited by
MPEP in both rat and mouse hippocampal slices (Faas
et al., 2002; Hou and Klann, 2004) and is absent in
mGluR5 mutant mice (Huber et al., 2001). Thus, both
mGluR-LTD and the LTD-associated increases in FMRP
synthesis depend on activation of mGluR5. In addition,
these findings are consistent with the idea that the
lack of mGluR5-dependent FMRP synthesis contributes
to the enhanced mGluR-LTD observed in Fmr1 knock-
out mice.One of the most intriguing observations in the work
described herein is the observation that the rapid in-
crease in FMRP synthesis associated with mGluR-LTD
is transient and followed by a rapid decrease in FMRP
levels back to baseline (Figure 1). Our observations are
consistent with a previous finding that novel visual expe-
rience results in a rapid increase in FMRP levels in the
cell bodies and dendrites of visual cortical neurons,
which quickly returns to baseline levels (Gabel et al.,
2004). Taken together, these findings suggest that FMRP
is dynamically regulated during certain forms of synap-
tic plasticity, including mGluR-LTD, with rapid synthesis
followed by rapid degradation. Consistent with this no-
tion, we found that two structurally distinct proteasome
inhibitors, MG132 and lactacystin, blocked the decline
of FMRP levels during mGluR-LTD (Figure 3), thereby
implicating a role for the ubiquitin-proteasome degrada-
tion pathway in FMRP regulation during mGluR-LTD.
The ubiquitin-proteasome system marks proteins to be
degraded by the attachment of a polyubiquitin chain
to the target protein (Pickart, 1997, 2000). mGluR-LTD
appears to result in this type of targeted degradation
of FMRP because we found that FMRP was polyubiqui-
tinated in the same temporal window in which FMRP
levels begin to decline (Figures 1 and 4A–4D). These
findings in their entirety suggest that not only FMRP
synthesis, but also FMRP degradation, plays a critical
role in mGluR-LTD.
Several studies have shown that the ubiquitin-protea-
some pathway plays a major role in regulating several
forms of synaptic plasticity (Chain et al., 1999; Colledge
et al., 2003; Hegde and DiAntonio, 2002; Speese et al.,
2003; Zhao et al., 2003). Here, we found that the ubiqui-
tin-proteasome pathway also is critical for mGluR-LTD
as we found that LTD was blocked by proteasome inhib-
itors (Figures 4E–4H). We considered the possibility that
the rapid degradation of FMRP might be required to per-
mit its target mRNAs to be translated, thereby consoli-
dating mGluR-LTD. Consistent with this possibility, we
found that mGluR-LTD was abolished in FMR1 YAC
transgenic mice that overexpress human FMRP (Fig-
ure 5). In addition, we found that FMRP was required
for the ability of the proteasome inhibitor to block
mGluR-LTD, as LTD in Fmr1 knockout mice was no
longer sensitive to inhibition of ubiquitin-proteasome
pathway (Figure 6). Taken together, these findings sug-
gest a new specific model whereby synthesis, ubiquiti-
nation, and proteolysis of FMRP provides a dynamic
regulatory system for controlling mGluR-LTD in hippo-
campal area CA1.
FMRP contains three RNA binding domains: two K ho-
mology (KH) domains and one RGG box (Ashley et al.,
1993; Siomi et al., 1993). Previous studies have shown
that the RGG box of FMRP specifically binds RNAs con-
taining G-quartet motifs (Darnell et al., 2001; Schaeffer
et al., 2001). The mRNA of MAP1B, which contains this
structure, is a predicted target of FMRP (Brown et al.,
2001; Darnell et al., 2001; Zalfa et al., 2003), although
FMRP also may bind additional mRNAs without a G-
quartet motif (Zhang et al., 2001; Kanai et al., 2004).
It has been shown that the mRNAs of MAP1B and a-
CaMKII are translated more efficiently in the Fmr1 knock-
out mice compared to wild-type mice, which suggests
that FMRP represses the translation of the mRNAs of
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451MAP1B and a-CaMKII in the normal mouse brain (Zalfa
et al., 2003; Lu et al., 2004). Consistent with these find-
ings, we observed that the basal levels of MAP1B and
a-CaMKII were significantly increased in hippocampal
area CA1 of Fmr1 knockout mice compared to wild-
type mice (Figure 7). This finding is consistent with the
mGluR theory of fragile X mental retardation in which
there is excessive translation of FMRP target mRNAs
in Fmr1 knockout mice. Also consistent with this theory,
we found that mGluR-LTD was associated with a rapid
increase in the levels of MAP1B and a-CaMKII in wild-
type mice. However, in the Fmr1 knockout mice,
mGluR-LTD did not result in an additional increase in
the levels of MAP1B and a-CaMKII. Our results are con-
sistent with a previous study that showed that activation
of group I mGluRs elicit a rapid peak of polyribosome
aggregates in synaptoneurosomes from wild-type
mice, but not in synaptoneurosomes from Fmr1 knock-
out mice (Weiler et al., 2004). In the same study, it was
demonstrated that activation of group I mGluRs also
induced increased incorporation of radiolabeled methi-
onine into synaptoneurosomal proteins in wild-type
mice, but not in Fmr1 knockout mice (Weiler et al.,
2004). Finally, it was shown that mGluR-dependent syn-
thesis of the synaptic protein PSD95, whose mRNA also
binds to FMRP, was abrogated in cortical neuronal cul-
tures from Fmr1 knockout mice (Todd et al., 2003a).
Thus, excessive translation of FMRP binding mRNAs
during development may occur in the Fmr1 knockout
mice. In addition, it appears that mGluR-dependent
translation of these mRNAs is improperly regulated in
Fmr1 knockout mice.
A previous report from Huber et al. (2002) and studies
described herein (Figure 5) indicate that mGluR-LTD is
enhanced in Fmr1 knockout mice. However, our studies
(Figure 7) and those of Weiler et al. (2004) indicate that
mGluR-dependent protein synthesis is regulated im-
properly in Fmr1 knockout mice. These findings sug-
gested the possibility that protein synthesis is not re-
quired for mGluR-LTD in the Fmr1 knockout mice.
Consistent with this possibility, we observed that the
protein synthesis inhibitor anisomycin, which blocked
mGluR-LTD in wild-type mice, did not affect the
mGluR-LTD in Fmr1 knockout mice (Figure 8), similar
to recent findings by Nosyreva and Huber (2006). In
addition, it has been reported that the ERK signaling
pathway plays an important role in the protein synthe-
sis-dependence of mGluR-LTD (Gallagher et al., 2004;
Banko et al., 2006). However, we found that in contrast
to wild-type mice, inhibition of ERK activity with U0126
could not block the enhanced mGluR-LTD in the Fmr1
knockout mice (Figure 9). Taken together, these results
indicate that the enhancement of mGluR-LTD in Fmr1
knockout mice does not require protein synthesis, per-
haps because the ‘‘LTD proteins’’ are elevated due to
excessive translation during development. Regardless,
it seems clear that the lack of FMRP alters the basic bio-
chemical signaling mechanisms underlying mGluR-LTD
in the hippocampus. It has been reported that Fmr1
knockout mice exhibit immature dendritic spine mor-
phology similar to that observed in human patients
with fragile X mental retardation (Irwin et al., 2001).
Moreover, a recent study described a developmental
switch in the biochemical signaling mechanisms thatare required to support mGluR-LTD. For example, in
neonatal (P8–P15) rats, protein synthesis inhibitors do
not block mGluR-LTD (Nosyreva and Huber, 2005). In
contrast, in adolescent (P21–P35) rats, the same protein
synthesis inhibitors block mGluR-LTD (Nosyreva and
Huber, 2005). All together, these findings suggest that
the genetic deletion of FMRP may result in stunted neu-
ronal development in Fmr1 knockout mice, which re-
sults in mGluR-LTD in the adult Fmr1 knockout mouse
more closely resembling mGluR-LTD in the neonatal
mouse. A possible candidate molecule to examine
would be MAP1B, which plays a principle role in neurite
and synapse development (Gonzalez-Billault et al.,
2004). Previous studies have shown that futsch, a Dro-
sophila MAP1B homolog, is required for the proper es-
tablishment of the neuronal cytoskeleton and normal
synaptic growth (Hummel et al., 2000; Roos et al.,
2000). In addition, FMRP has been shown to control
MAP1B and microtubule stability during neuronal devel-
opment in mice (Lu et al., 2004). Further experiments will
be necessary to determine whether improper develop-
mental regulation of MAP1B contributes to the en-
hanced mGluR-LTD observed in Fmr1 knockout mice.
In summary, our studies indicate that mGluR-LTD is
associated with the rapid translation, followed by the
rapid ubiquitination and degradation, of FMRP. Our
studies also indicate that the degradation of FMRP is re-
quired for mGluR-LTD. In addition, genetic deletion of
FMRP results in mGluR-LTD that is mechanistically dis-
tinct from mGluR-LTD in wild-type mice. Our findings
suggest novel models whereby synthesis, ubiquitina-
tion, and proteolysis of FMRP provides a dynamic regu-
latory system for controlling synaptic plasticity in the
hippocampus (Figure 10).
Experimental Procedures
Materials
DHPG, LY367385, and U0126 were obtained from Tocris Cookson
(Ellisville, Missouri). N-ethylmaleimide, MG132, clasto-lactacystin
b-lactone, and anti-MAP2 were purchased from Sigma (St. Louis,
Missouri). Anisomycin was obtained from Calbiochem (San Diego,
California). 2-methyl-6-(phenlethynyl)-pyridine (MPEP) was from
FRAXA Research Foundation. The anti-FMRP antibody for Western
blot was purchased from Chemicon Company (Temecula, Califor-
nia). The anti-FMRP 7G-1 antibody for immunoprecipitation experi-
ments was a gift from Dr. Stephanie Ceman of the University of Illi-
nois. The anti-MAP1B antibody was purchased from Santa Cruz
Technology (Santa Cruz, California), and the anti-ubiquitin antibody
was purchased from BD Biosciences (San Jose, California). The
horseradish peroxidase-linked goat anti-mouse IgG was from Prom-
ega (Madison, Wisconsin). Indocarbocyanine (Cy3)-conjugated affi-
niPure goat anti-mouse IgG and FITC-conjugated affiniPure goat
anti-rabbit IgG were obtained from Jackson Immunoresearch
(West Grove, Pennsylvania).
Animals
Male Fmr1 KO and wt littermates were generated by mating female
Fmr1 heterozygous (Fmr12y) mice with Fmr1 or wt male mice. The
Fmr1 mutation was backcrossed onto the C57BL/6J genetic back-
ground for 12 generations. The FMR1 YAC-overexpressing mice
were generated as described (Peier et al., 2000). For the current
study, we mated C57BL/6J (N11–N12) female Fmr1 heterozygous
(Fmr12y) mice with C57BL/6J inbred male YAC FMRP-overexpress-
ing mice to obtain male wt, Fmr1 KO, FMR1 YAC, and Fmr1 KO +
FMR1 YAC mice. Mice were housed 2–5 per cage in a room with
a 12 hr light:dark cycle. The mice had access to food and water ad
libitum. For other experiments, C57BL/6J male mice were used. All
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452Figure 10. Models for the Dynamic Regulation of FMRP during mGluR-LTD
(A) Activation of group I mGluRs stimulates synthesis of a set of proteins, some of which may contribute to AMPA receptor internalization (Snyder
et al., 2001), thereby resulting in mGluR-LTD. In response to mGluR activation, the levels of FMRP also are increased, followed by the rapid ubiq-
uitination and degradation of FMRP, with the latter process permitting FMRP binding mRNAs to be translated. Increased FMRP levels, achieved
by either overexpression of FMRP or inhibiting the ubiquitin-proteasome pathway, block mGluR-LTD by inhibiting the translation of FMRP target
mRNAs.
(B) Alternatively, activation of mGluRs triggers the ubiquitination and degradation of FMRP, permitting FMRP binding mRNAs to be translated. It
also is possible that monoubiquitination of FMRP (Figures 4A and 4B) is required for FMRP binding mRNAs to be translated, independent of the
degradation of FMRP.procedures were approved by the Baylor College of Medicine Ani-
mal Care and Use Committee and followed the NIH Guidelines for
the use of animals in research.
Hippocampal Slice Preparations
Hippocampal slices from Fmr1 knockout mice and C57BL/6 wild-
type mice 4 to 6 weeks of age were removed, and 400 mm slices
were prepared as previously described (Hou and Klann, 2004).
Briefly, slices were placed in saline solution (110 mM sucrose,
60 mM NaCl, 3 mM KCl, 1.25 mM NaH2PO4, 28 mM NaHCO3,
5 mM D-glucose, 0.5 mM CaCl2, and 7 mM MgCl2, gassed with
95% O2/5% CO2 [pH 7.4]) for 30 min at room temperature, then
transferred to a 32C artificial cerebrospinal fluid (ACSF) containing
(125 mM NaCl, 2.5 mM KCl, 1.25 mM NaH2PO4, 25 mM NaHCO3,
2 mM CaCl2, 1 mM MgCl2, 25 mM D-glucose saturated 95%
O2/5% CO2 [pH 7.4]) for 1 hr. Slices then were exposed to different
compounds of interest for the indicated times and snap frozen
over dry ice. For biochemical experiments, the CA1 regions were mi-
crodissected and sonicated in ice-cold homogenization buffer (HB)
containing phosphatase and protease inhibitors (200 nM calyculin,
10 mg/ml leupeptin, 2 mg/ml aprotinin, 1 mM sodium orthovanadate,
and 1 mM microcystin-LR). The protein concentration was measured
by the method of Bradford (1976) using bovine serum albumin as
the standard.
Western Blot Analysis
Immunoblot analysis was conducted as previously described (Hou
and Klann, 2004). The primary antibodies were diluted as follows:
FMRP antibody (1C3), 1:2500; MAP1B antibody, 1:100; a-CaMKII
antibody, 1:10,000; a-tubulin antibody, 1:5,000; P-ERK antibody,
1:3000; T-ERK antibody, 1:5000. The bands of each Western blot
were quantified from film exposures in the linear range for each
antibody and normalized to a-tubulin immunoreactivity with densi-
tometry using a desktop scanner and Scion image software (Scion
Corporation) to determine the amount of immunoreactivity.
Immunocytochemistry
The immunofluorescent staining was conducted as previously de-
scribed (Hou and Klann, 2004). Briefly, DHPG-treated and control sli-
ces were fixed with ice-cold 4% paraformaldehyde in PBS (pH 7.4)
and embedded with O.C.T. The slices were cut into 25 mm sectionsusing a microtome. Free-floating sections were blocked and in-
cubated with primary antibodies (FMRP antibody, 1:200; MAP2
antibody, 1:1000), then incubated with CY3-conjugated affiniPure
goat anti-mouse IgG and FITC-conjugated affiniPure anti-rabbit IgG
(Jackson Immunoresearch Laboratories) diluted 1:500 in blocking
solution. Sections were mounted onto slides with VECTASHIELD
mounting medium with 406-diamidion-2-phenylindole (DAPI) (Vector
Laboratories, Burlingame, California). Sections then were analyzed
and imaged using a Zeiss LSM 510 meta confocal microscope
system (Zeiss, Oberkochen, Germany). For visualization of FITC,
a HeNe1 laser was used with a 488 nm emission, for visualization
of CY3, an Argon/2 laser was used with a 543 nm emission, and
for visualization of DAPI, a UV laser was used with a 460 nm emis-
sion. A Z series projection of approximately six to ten images with
1.6 to 2.5 depth intervals each were averaged four times. All the
parameters (pinhole, gain, contrast, and brightness) were kept con-
stant for slices from the same experiment. For quantification of
FMRP staining in dendrites, puncta were defined as region of stain-
ing overlapping MAP2. Each experiment was repeated a minimum of
five times, imaging at least 10 dendrite puncta. Puncta were delin-
eated manually and average pixel intensity was measured using
Adobe Photoshop 7.0 software. Because FMRP also is present in
glial cells (Wang et al., 2004), it is possible that FMRP staining over-
lapping with MAP2 is due to background staining in glia.
Immunoprecipitation of FMRP
Hippocampal slices were prepared as described and exposed to dif-
ferent compounds of interest for the indicated times and snap frozen
over dry ice. The CA1 regions were microdissected and sonicated
in ice-cold lysis buffer (50 mM Tris-HCl [pH 8.0], 300 mM NaCl, 1%
Triton X-100, 1 mM EDTA, 1 mM EGTA) in the presence of protease
inhibitors (aprotinin 2mg/ml, leupeptin 10mg/ml, and pepstatin 1mg/ml)
and 50 mM N-ethylmaleimide, which inhibits deubiquitinating
enzymes. Fifty microliters of protein A Sepharose was preincubated
with FMRP 7G1-1 antibody rotating at 4C overnight to couple the
antibody to the beads. Then hippocampal area CA1 lysates were
added to the bead-antibody conjugated complex to promote bind-
ing of endogenous FMRP at 4C for 3 hr. Beads then were washed
in lysis buffer five times. The immunoprecipitate was loaded onto
10% SDS-PAGE and analyzed by Western blotting for ubiquitinated
FMRP with a ubiquitin antibody (1:2500). Shown in Figure S2
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453are positive control experiments that were conducted to detect
ubiquitinated IkB in hippocampal slices in response to treatment
with tumor necrosis factor a (TNFa). IkB is polyubiquitinated in re-
sponse to diverse signals, including TNFa, in nonneuronal cells
(Chen, 2005).
Electrophysiological Recordings
Extracellular recordings were conducted as previously described
(Hou and Klann, 2004). The 400 mm thick slices were prepared as de-
scribed earlier. The slices were placed into an interface recording
chamber and equilibrated with oxygenated ACSF at a flow rate of
1 ml/min at 30C for at least 1 hr before recording. Extracellular re-
cordings of field excitatory postsynaptic potentials (fEPSPs) were
obtained from the stratum radiatum using microelectrodes filled
with ACSF (resistance 1–4 MU). A bipolar Teflon-coated platinum
electrode was placed in stratum radiatum to activate Schaffer collat-
eral/commissural afferents at 0.05 Hz. The stimulation strength was
set to elicit a response equivalent to 50% of the maximal fEPSPs. For
each 2 min interval, the traces were automatically averaged via
Patch Clamp analysis software. In all experiments, baseline synaptic
transmission was monitored for a minimum of 10 min before drug
administration. The slope of the fEPSP was expressed as percent
of the baseline average before drug application. Normalized data
were averaged and expressed as the mean 6 SEM. Significant dif-
ferences between groups were determined using either ANOVA
analysis followed by Newman-Keuls post test or unpaired t test
performed on a 10 min average after DHPG application.
Supplemental Data
The Supplemental Data for this article can be found online at http://
www.neuron.org/cgi/content/full/51/4/441/DC1/.
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